- Home
- ZIMV
ZIMV
ZimVie Inc.
as 04-18-2025 1:45pm EST
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | PALM BEACH GARDEN |
| Market Cap: | 262.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 155.1K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.56 - $22.40 | Next Earning Date: | 05-07-2025 |
| Revenue: | $449,749,000 | Revenue Growth: | -1.68% |
| Revenue Growth (this year): | 1.9% | Revenue Growth (next year): | 2.61% |
Latest ZimVie Inc. News
ZIMV Breaking Stock News: Dive into ZIMV Ticker-Specific Updates for Smart Investing
GlobeNewswire
25 days ago
ZimVie to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
a month ago
ZimVie Announces Upcoming Changes to Company's Board of Directors
Investing.com
a month ago
Needham cuts Dentsply Sirona and ZimVie to ‘hold’ on weak dental market outlook
Thomson Reuters StreetEvents
2 months ago
Q4 2024 ZimVie Inc Earnings Call
GuruFocus.com
2 months ago
ZimVie Inc (ZIMV) Q4 2024 Earnings Call Highlights: Strong Cash Flow and Margin Improvements ...
Motley Fool
2 months ago
ZimVie (ZIMV) Q4 2024 Earnings Call Transcript
GlobeNewswire
2 months ago
ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
2 months ago
ZimVie to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Compare ZIMV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZIMV ZimVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.